ATE460498T1 - Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen - Google Patents

Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen

Info

Publication number
ATE460498T1
ATE460498T1 AT04774932T AT04774932T ATE460498T1 AT E460498 T1 ATE460498 T1 AT E460498T1 AT 04774932 T AT04774932 T AT 04774932T AT 04774932 T AT04774932 T AT 04774932T AT E460498 T1 ATE460498 T1 AT E460498T1
Authority
AT
Austria
Prior art keywords
producing
polysaccharide
conjugate vaccines
capsule polysaccharide
base
Prior art date
Application number
AT04774932T
Other languages
English (en)
Inventor
Ahd Hamidi
Michel Beurret
Original Assignee
Staat Der Nederlanden Vert Doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staat Der Nederlanden Vert Doo filed Critical Staat Der Nederlanden Vert Doo
Application granted granted Critical
Publication of ATE460498T1 publication Critical patent/ATE460498T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT04774932T 2003-09-11 2004-09-10 Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen ATE460498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077881 2003-09-11
PCT/NL2004/000627 WO2005024038A2 (en) 2003-09-11 2004-09-10 Process for producing a capsular polysaccharide for use in conjugate vaccines

Publications (1)

Publication Number Publication Date
ATE460498T1 true ATE460498T1 (de) 2010-03-15

Family

ID=34259185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04774932T ATE460498T1 (de) 2003-09-11 2004-09-10 Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen

Country Status (12)

Country Link
US (1) US7582459B2 (de)
EP (1) EP1664319B1 (de)
KR (1) KR101161033B1 (de)
AT (1) ATE460498T1 (de)
CA (1) CA2538691C (de)
DE (1) DE602004025951D1 (de)
DK (1) DK1664319T3 (de)
ES (1) ES2341863T3 (de)
PL (1) PL1664319T3 (de)
PT (1) PT1664319E (de)
SI (1) SI1664319T1 (de)
WO (1) WO2005024038A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3311836A1 (de) 2005-04-08 2018-04-25 Wyeth LLC Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0522303D0 (en) * 2005-11-01 2005-12-07 Chiron Srl Culture method
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
KR101045881B1 (ko) * 2008-09-11 2011-07-01 전남대학교산학협력단 연쇄상구균으로부터의 협막다당 생산 배지, 생산 방법 및 정제 방법
BRPI0922981A8 (pt) * 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
ES2749952T3 (es) 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
DE102009022251A1 (de) * 2009-05-20 2010-11-25 Technische Universität Bergakademie Freiberg Verfahren und Mittel zur extraktiven Gewinnung organischer Substanzen
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011148382A1 (en) * 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
CN102175841A (zh) * 2010-12-30 2011-09-07 北京民海生物科技有限公司 一种脑膜炎球菌多糖结合物中游离多糖含量的测定方法
CN104080904B (zh) * 2011-12-15 2017-06-30 血清研究所印度私人有限公司 培养细菌以提高荚膜多糖产率的新方法
CN102628068B (zh) * 2012-04-23 2013-09-04 成都欧林生物科技股份有限公司 b型流感嗜血杆菌高密度培养生产细菌荚膜多糖的方法
CN104487086B (zh) 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
JP6502262B2 (ja) * 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
US11027005B2 (en) 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US5316926A (en) * 1983-11-25 1994-05-31 Miles Inc. Method for the microbiological production of non-antigenic hyaluronic acid
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
GB9024223D0 (en) * 1990-11-07 1990-12-19 Fermentech Ltd Production of hyaluronic acid
US6410025B1 (en) * 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
ES2229477T3 (es) * 1997-01-24 2005-04-16 Berna Biotech Ag Procedimiento nuevo para el aislamiento de polisacaridos.

Also Published As

Publication number Publication date
WO2005024038A2 (en) 2005-03-17
PL1664319T3 (pl) 2010-07-30
DK1664319T3 (da) 2010-05-10
WO2005024038A3 (en) 2005-12-29
KR20060092234A (ko) 2006-08-22
CA2538691A1 (en) 2005-03-17
SI1664319T1 (sl) 2010-06-30
EP1664319B1 (de) 2010-03-10
KR101161033B1 (ko) 2012-06-28
US20070065460A1 (en) 2007-03-22
EP1664319A2 (de) 2006-06-07
US7582459B2 (en) 2009-09-01
DE602004025951D1 (de) 2010-04-22
ES2341863T3 (es) 2010-06-29
CA2538691C (en) 2014-01-14
PT1664319E (pt) 2010-06-17

Similar Documents

Publication Publication Date Title
ATE460498T1 (de) Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen
ATE506448T1 (de) Verfahren zur l-aminosäureherstellung mittels fermentation
DE50112855D1 (de) Verfahren zur Herstellung von Knorpelimplantaten mittels in vitro gezüchteter Chondrozyten
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
ATE488574T1 (de) Verfahren zur herstellung eines immunogenen faktors von corynebacterium diphtheriae unter verwendung eines kulturmediums mit hefeextrakt als aminosäurenquelle und ohne proteinkomplexe tierischer herkunft
ATE542886T1 (de) Verfahren zur herstellung von l-arginin mit corynebacterium glutamicum
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
CY1108329T1 (el) Κυτταρικη καλλιεργεια
ATE528026T1 (de) Verfahren zur herstellung eines künstlichen gelenks
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
ATE360653T1 (de) Verfahren zur herstellung von polyisobutenen
WO2005103230A3 (en) Soy peptone as a nitrogen source in preparing meningococcal conjugates
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
ATE361108T1 (de) Verwendung eines hydrogels zum züchten von chondrozyten
ATE460950T1 (de) Vernetzte kollagenmatrix zur herstellung eines hautäquivalentes
ATE375165T1 (de) Verfahren zur herstellung eines extraktes aus efeublättern
ATE414760T1 (de) Verfahren zur herstellung einer epithelzellen enthaltenden zellzusammensetzung
ATE476426T1 (de) Verfahren zur herstellung von alkoxycarbonylamino-triazinen
SE9903534D0 (sv) Vaccin
ATE464375T1 (de) Verfahren zur herstellung von virusmaterial
TR200606983T1 (tr) Nodavirüs-VLP bağışıklaştırma bileşimi
AR052142A1 (es) Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
ATE392413T1 (de) Verfahren zur herstellung von beta-alaninamiden
ATE309344T1 (de) Verfahren zur aufbereitung von biomasse zur herstellung von plasmid dna haltigem zelllysat
ATE412046T2 (de) Verfahren zur rehydratation von aktiven trockenen hefen und rehydratationsmedium

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1664319

Country of ref document: EP